ArticleNPJ breast cancer2026
Monitoring of circulating tumor DNA in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy.
Article in NPJ breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Integration of Nanotechnology with ctDNA: New Advances for Monitoring Neoadjuvant Chemotherapy.International journal of nanomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
Circulating tumor DNA (ctDNA) has potential as a prognostic factor for predicting relapse in high-risk breast cancer (BC). This study investigates the utility of ctDNA assessment using a tumor-informed assay, in patients with high-risk BC treated with neoadjuvant chemotherapy (NAC). Thirty newly diagnosed patients with various high-risk BC subtypes participated, providing serial blood samples at multiple time points, including baseline, during NAC, and during follow-up. ctDNA was detected at baseline in 29/29 patients for whom an assay panel could be designed, with detection sensitivity reaching 0.0083% (variant allele frequency). Among patients with detectable baseline ctDNA, 94% showed clearance during treatment, correlating with improved outcomes. Additionally, ctDNA detection post-surgery or during follow-up predicted disease recurrence. These findings suggest that serial ctDNA monitoring throughout NAC and follow-up can effectively identify residual disease in BC and correlate with clinical outcomes.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.